Research and Markets: China Animal Vaccine Industry Report, 2013-2016

In 2004-2013, Chinese animal vaccine market size maintained a high growth rate of 26.3%, reaching about RMB11.5 billion in 2013. The growth in 2007-2010 was mainly driven by the expansion of governmental tender vaccine, while that from 2011 was primarily thanks to the market-oriented vaccine expansion. The Chinese animal vaccine market is basically occupied by local companies, showing a self-sufficiency rate of around 90%.

Given the policy factor, Chinese animal vaccine products are divided into compulsory immunization vaccines and market-oriented vaccines. At present, the former include foot-and-mouth disease (FMD), bird flu, porcine reproductive and respiratory syndrome (PRRS), swine fever, and peste des petits ruminants (PPR); the latter refer to porcine circovirus (PCV), Newcastle disease, porcine parvovirus (PPV) and other varieties. Since 2011, the bids for compulsory vaccines proposed by the Chinese government has turned to be more fierce, with limited growth potential; however, market-oriented vaccines have developed faster, enjoying 40%-50% market share in 2013.

As the scale of Chinese farming escalates, the demand for animal vaccines will continue to grow steadily. In the next few years, the Chinese animal vaccine industry is expected to keep a growth rate of approximately 15% and see market value of RMB17.5 billion or so in 2016.

1. Overview of Animal Vaccine

2. Status Quo of Animal Vaccine Industry

3. Development Environment for China Animal Vaccine Industry

4. Chinese Animal Vaccine Industry Segments

5. Key Enterprises

6. Summary and Forecast